PainReform Ltd.(PRFX)Earnings, Financials & Key Ratios
PRFX•NASDAQ
$1.90
$861734 mkt cap·Price updated May 7, 2026
AboutPainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.Show more
- Revenue$0
- EBITDA-$15M-53.2%
- Net Income-$15M-56.1%
- EPS (Diluted)-32.16+81.2%
- ROE-321.92%-214.6%
- Debt/Equity0.02+107.7%
- Interest Coverage-1048.07-4099.3%
PRFX Key Insights
PainReform Ltd. (PRFX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRFX Price & Volume
PainReform Ltd. (PRFX) stock price & volume — 10-year historical chart
Loading chart...
PRFX Growth Metrics
PainReform Ltd. (PRFX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM76.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.84%
Return on Capital
10 Years-336.49%
5 Years-107.45%
3 Years-155.87%
Last Year-305.59%
PRFX Peer Comparison
PainReform Ltd. (PRFX) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCRX | 929.88M | 23.64 | 147.75 | 3.63% | 1.27% | 1.31% | 0.66 | |
 ACRS | 585.63M | 4.86 | -9.17 | -58.19% | -8.3% | -62.98% | ||
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 XTLB | 293.77K | 2.67 | -0.28 | -227.72% | -25.53% | 0.03 | ||
 BHC | 2.14B | 5.73 | 13.31 | 8.53% | -11.27% | 5.88% | 56.36 | |
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 DARE | 25.32M | 2.91 | -6.06 | -99.65% | -6.11% |
Compare PRFX vs Peers
PainReform Ltd. (PRFX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRFX Income Statement
PainReform Ltd. (PRFX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 86K | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | -100% | - | - |
| Cost of Goods Sold | 0 | 0 | 1K | 0 | 7K | 15K | 15K | 16K | 0 |
| COGS % of Revenue | - | - | - | - | - | 17.44% | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -1K▲ 0% | 0▲ 100.0% | -7K▲ 0% | 71K▲ 1114.3% | -15K▼ 121.1% | -16K▼ 6.7% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | 82.56% | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | - | 1114.29% | -121.13% | -6.67% | - |
| Operating Expenses | 877K | 500K | 689K | 1.67M | 7.21M | 8.87M | 9.58M | 14.66M | 4.13M |
| OpEx % of Revenue | - | - | - | - | - | 10312.79% | - | - | - |
| Selling, General & Admin | 376K | 277K | 553K | 1.32M | 4.35M | 4.45M | 3.55M | 2.95M | 3.38M |
| SG&A % of Revenue | - | - | - | - | - | 5170.93% | - | - | - |
| Research & Development | 504K | 223K | 136K | 354K | 2.86M | 4.42M | 6.04M | 11.71M | 576K |
| R&D % of Revenue | - | - | - | - | - | 5141.86% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 173K |
| Operating Income | -880K▲ 0% | -500K▲ 43.2% | -689K▼ 37.8% | -1.67M▼ 142.5% | -7.21M▼ 331.4% | -8.87M▼ 23.0% | -9.58M▼ 8.1% | -14.67M▼ 53.1% | -4.13M▲ 0% |
| Operating Margin % | - | - | - | - | - | -10312.79% | - | - | - |
| Operating Income Growth % | - | 43.18% | -37.8% | -142.53% | -331.36% | -23.04% | -8.06% | -53.1% | - |
| EBITDA | 0 | 0 | -688K | -1.67M | -7.2M | -8.85M | -9.57M | -14.66M | -3.94M |
| EBITDA Margin % | - | - | - | - | - | -10295.35% | - | - | - |
| EBITDA Growth % | - | - | - | -142.73% | -331.2% | -22.96% | -8.08% | -53.17% | 77.87% |
| D&A (Non-Cash Add-back) | 880K | 500K | 1K | 1K | 7K | 15K | 15K | 16K | 190K |
| EBIT | -880K | -503K | -689K | -1.67M | -7.23M | -8.77M | -9.58M | -14.57M | -4.13M |
| Net Interest Income | 0 | 0 | -540.41K | -985.95K | -10K | 99K | 22K | 87K | 3K |
| Interest Income | 245K | 0 | 588 | 1.05K | 0 | 160K | 406K | 101K | 3K |
| Interest Expense | 0 | 324K | 541K | 987K | 10K | 61K | 384K | 14K | 0 |
| Other Income/Expense | -242K | -328K | -590K | -2.16M | -32K | 86K | 248K | 93K | 53K |
| Pretax Income | -1.12M▲ 0% | -828K▲ 26.2% | -1.28M▼ 54.5% | -3.83M▼ 199.7% | -7.24M▼ 88.9% | -8.78M▼ 21.3% | -9.34M▼ 6.3% | -14.58M▼ 56.2% | -4.08M▲ 0% |
| Pretax Margin % | - | - | - | - | - | -10212.79% | - | - | - |
| Income Tax | 0 | 4K | 0 | 220K | 6K | 9K | 8K | 8K | 8K |
| Effective Tax Rate % | 0% | -0.48% | 0% | -5.74% | -0.08% | -0.1% | -0.09% | -0.05% | -0.2% |
| Net Income | -2.09M▲ 0% | -828K▲ 60.4% | -1.82M▼ 119.8% | -4.05M▼ 122.7% | -7.25M▼ 78.8% | -8.79M▼ 21.3% | -9.34M▼ 6.3% | -14.59M▼ 56.1% | -4.09M▲ 0% |
| Net Margin % | - | - | - | - | - | -10223.26% | - | - | - |
| Net Income Growth % | - | 60.38% | -119.81% | -122.69% | -78.78% | -21.34% | -6.28% | -56.12% | 76.88% |
| Net Income (Continuing) | -1.12M | -828K | -1.28M | -4.05M | -7.25M | -8.79M | -9.34M | -14.59M | -4.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -36.25▲ 0% | -48.32▼ 33.3% | -62.11▼ 28.5% | -83.05▼ 33.7% | -177.23▼ 113.4% | -197.92▼ 11.7% | -171.33▲ 13.4% | -32.16▲ 81.2% | -1.92▲ 0% |
| EPS Growth % | - | -33.3% | -28.55% | -33.71% | -113.4% | -11.67% | 13.44% | 81.23% | 98.84% |
| EPS (Basic) | -36.67 | -14.53 | -62.11 | -83.05 | -177.23 | -197.92 | -171.33 | -32.16 | - |
| Diluted Shares Outstanding | 57.66K | 57.66K | 38.78K | 48.8K | 40.88K | 44.42K | 54.54K | 453.54K | 2.12M |
| Basic Shares Outstanding | 57K | 57K | 38.78K | 48.8K | 40.88K | 44.42K | 54.54K | 453.54K | 2.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PRFX Balance Sheet
PainReform Ltd. (PRFX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 213K | 80K | 972K | 17.79M | 19.02M | 12.28M | 9.8M | 4.43M | 3.91M |
| Cash & Short-Term Investments | 187K | 40K | 941K | 15.68M | 16.54M | 4.1M | 8.03M | 4.26M | 3.48M |
| Cash Only | 187K | 40K | 941K | 15.68M | 16.54M | 4.1M | 8.03M | 4.26M | 3.48M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 28K | 22K | 53K | 218K | 55K | 45K | 119K | 0 |
| Days Sales Outstanding | - | - | - | - | - | 233.43 | - | - | - |
| Inventory | 0 | 0 | 0 | 2.04M | 0 | 7.82M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | 190.36K | - | - | - |
| Other Current Assets | 26K | 6K | 6K | 33K | 507K | 0 | 10K | 10K | 15K |
| Total Non-Current Assets | 1K | 1K | 192K | 10K | 53K | 44K | 131K | 97K | 7.25M |
| Property, Plant & Equipment | 1K | 1K | 0 | 10K | 53K | 44K | 131K | 97K | 84K |
| Fixed Asset Turnover | - | - | - | - | - | 1.95x | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.12M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 192K | 0 | 0 | 0 | 0 | 0 | 100K |
| Total Assets | 214K▲ 0% | 81K▼ 62.1% | 1.16M▲ 1337.0% | 17.8M▲ 1429.3% | 19.07M▲ 7.1% | 12.33M▼ 35.4% | 9.93M▼ 19.5% | 4.53M▼ 54.4% | 11.16M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.01x | - | - | 0.00x |
| Asset Growth % | - | -62.15% | 1337.04% | 1429.3% | 7.15% | -35.36% | -19.45% | -54.43% | 254.28% |
| Total Current Liabilities | 135K | 18K | 6.34M | 961K | 757K | 1.06M | 2.41M | 2.44M | 2.46M |
| Accounts Payable | 64K | 2K | 0 | 720K | 136K | 209K | 221K | 296K | 164K |
| Days Payables Outstanding | - | - | - | - | 7.09K | 5.09K | 5.38K | 6.75K | - |
| Short-Term Debt | 0 | 0 | 6.17M | 0 | 0 | 0 | 0 | 45K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 71K | 16K | -166K | 0 | 0 | 0 | 465K | 152K | 0 |
| Current Ratio | 1.58x | 4.44x | 0.15x | 18.51x | 25.13x | 11.55x | 4.07x | 1.81x | 1.81x |
| Quick Ratio | 1.58x | 4.44x | 0.15x | 16.39x | 25.13x | 4.19x | 4.07x | 1.81x | 1.81x |
| Cash Conversion Cycle | - | - | - | - | - | 185.51K | - | - | - |
| Total Non-Current Liabilities | 3.71M | 4.52M | 447K | 220K | 234K | 243K | 281K | 259K | 263K |
| Long-Term Debt | 3.71M | 4.52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 30K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 220K | 234K | 243K | 251K | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 447K | 220K | 0 | 0 | 0 | 259K | 1.04M |
| Total Liabilities | 3.84M | 4.54M | 6.79M | 1.18M | 991K | 1.31M | 2.69M | 2.7M | 2.72M |
| Total Debt | 3.71M | 4.52M | 6.17M | 0 | 0 | 0 | 86K | 45K | 56K |
| Net Debt | 3.52M | 4.48M | 5.23M | -15.68M | -16.54M | -4.1M | -7.94M | -4.22M | -3.42M |
| Debt / Equity | - | - | - | - | - | - | 0.01x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.87x |
| Interest Coverage | - | -1.54x | -1.27x | -1.69x | -720.80x | -145.39x | -24.96x | -1048.07x | - |
| Total Equity | -3.63M▲ 0% | -4.46M▼ 22.8% | -5.62M▼ 26.1% | 16.62M▲ 395.6% | 18.08M▲ 8.8% | 11.02M▼ 39.0% | 7.24M▼ 34.3% | 1.82M▼ 74.8% | 8.44M▲ 0% |
| Equity Growth % | - | -22.82% | -26.14% | 395.62% | 8.8% | -39.05% | -34.32% | -74.8% | 716.85% |
| Book Value per Share | -62.94 | -77.30 | -144.96 | 340.57 | 442.28 | 248.10 | 132.73 | 4.02 | 3.98 |
| Total Shareholders' Equity | -3.63M | -4.46M | -5.62M | 16.62M | 18.08M | 11.02M | 7.24M | 1.82M | 8.44M |
| Common Stock | 5K | 5K | 5K | 78K | 94K | 94K | 147K | 0 | 0 |
| Retained Earnings | -10.32M | -11.15M | -12.43M | -16.48M | -23.73M | -32.52M | -41.86M | -56.45M | -58.77M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRFX Cash Flow Statement
PainReform Ltd. (PRFX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -870K | -635K | -609K | -2.56M | -6.55M | -6.46M | -6.68M | -12.62M | -12.62M |
| Operating CF Margin % | - | - | - | - | - | -7510.47% | - | - | - |
| Operating CF Growth % | - | 27.01% | 4.09% | -319.87% | -156.28% | 1.43% | -3.41% | -88.97% | 49.06% |
| Net Income | -1.12M | -828K | -1.28M | -4.05M | -7.25M | -8.79M | -9.34M | -14.59M | -4.09M |
| Depreciation & Amortization | 0 | 0 | 1K | 987K | 7K | 15K | 15K | 16K | 190K |
| Stock-Based Compensation | 18K | 0 | 89K | 38K | 812K | 1.39M | 804K | 310K | 112K |
| Deferred Taxes | 0 | 0 | 2K | -987K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 257K | 324K | 613K | 2.33M | 412K | 257K | 218K | -16K | 440K |
| Working Capital Changes | -23K | -131K | -35K | -869K | -538K | 672K | 1.63M | 1.66M | -2.62M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | -62K | -2K | 720K | -585K | 73K | 12K | 76K | 0 |
| Cash from Investing | 0 | 0 | 0 | -10K | -50K | -6.01M | 5.99M | -13K | -51K |
| Capital Expenditures | 0 | 0 | 0 | -10K | -50K | -6K | -9K | -13K | -1K |
| CapEx % of Revenue | - | - | - | - | - | 6.98% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -50K | -6K | 0 | 0 | -50K |
| Cash from Financing | 699K | 488K | 1.51M | 17.31M | 7.48M | 0 | 4.62M | 8.86M | 6.7M |
| Debt Issued (Net) | 699K | 488K | 241K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 1000K | 0 | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 1.27M | 0 | 1.48M | 0 | 2.91M | 3.51M | 6.7M |
| Net Change in Cash | -171K▲ 0% | -147K▲ 14.0% | 901K▲ 712.9% | 14.74M▲ 1536.3% | 881K▼ 94.0% | -12.46M▼ 1514.9% | 3.93M▲ 131.5% | -3.77M▼ 195.8% | -2.79M▲ 0% |
| Free Cash Flow | -870K▲ 0% | -635K▲ 27.0% | -609K▲ 4.1% | -2.57M▼ 321.5% | -6.6M▼ 157.2% | -6.46M▲ 2.1% | -6.69M▼ 3.4% | -12.63M▼ 88.9% | -5.96M▲ 0% |
| FCF Margin % | - | - | - | - | - | -7517.44% | - | - | - |
| FCF Growth % | - | 27.01% | 4.09% | -321.51% | -157.23% | 2.09% | -3.45% | -88.91% | 47.33% |
| FCF per Share | -15.09 | -11.01 | -15.70 | -52.60 | -161.51 | -145.54 | -122.63 | -27.86 | -27.86 |
| FCF Conversion (FCF/Net Income) | 0.42x | 0.77x | 0.33x | 0.63x | 0.90x | 0.73x | 0.71x | 0.87x | 1.46x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRFX Key Ratios
PainReform Ltd. (PRFX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -73.7% | -41.76% | -60.42% | -102.34% | -321.92% | -48.4% |
| Return on Invested Capital (ROIC) | -1630.43% | - | -453.25% | -434.57% | -157.07% | -230.98% | - | -235.79% |
| Gross Margin | - | - | - | - | 82.56% | - | - | - |
| Net Margin | - | - | - | - | -10223.26% | - | - | - |
| Debt / Equity | - | - | - | - | - | 0.01x | 0.02x | 0.02x |
| Interest Coverage | -1.54x | -1.27x | -1.69x | -720.80x | -145.39x | -24.96x | -1048.07x | - |
| FCF Conversion | 0.77x | 0.33x | 0.63x | 0.90x | 0.73x | 0.71x | 0.87x | 1.46x |
| Revenue Growth | - | - | - | - | - | -100% | - | - |
PRFX Frequently Asked Questions
PainReform Ltd. (PRFX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PainReform Ltd. (PRFX) grew revenue by 0.0% over the past year. Growth has been modest.
PainReform Ltd. (PRFX) reported a net loss of $4.1M for fiscal year 2024.
Dividend & Returns
PainReform Ltd. (PRFX) has a return on equity (ROE) of -321.9%. Negative ROE indicates the company is unprofitable.
PainReform Ltd. (PRFX) had negative free cash flow of $6.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More PRFX
PainReform Ltd. (PRFX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates